iPS細胞・再生医療研究グループ

①心筋再生

現在の治療法では効果が期待できない患者に対する次世代の治療としてES/iPS細胞を用いた心筋再生治療の開発が期待されています。当研究室では心筋分化誘導法の開発、心筋再生治療に適したiPS細胞株の樹立・選別法の開発、心筋細胞の効率の良い移植法の開発の研究を行い、iPS細胞より作製した心筋細胞を用いて、治療効果の高い再生医療を開発することを目指して研究を行っています。

②疾患特異的iPS細胞研究

患者の細胞から樹立したiPS細胞から誘導した細胞を用いて試験管内で疾患を再現することにより、疾患のメカニズムや創薬研究が可能になりました。疾患特異的iPS細胞研究はヒトの心筋細胞を安定して誘導することが可能になったことや、CRISPR/Cas9などの技術により遺伝子を編集することが可能になってきたこともあり、今後医学研究においてますます重要な役割をもつと思います。当研究室では心疾患(心筋症など)の患者の細胞から樹立したiPS細胞を用いて、疾患のメカニズム解析や治療薬の開発を目指しています。
iPS細胞による肥大型心筋症の病態モデルでは、ハイスループットスクリーニングにより治療薬の候補化合物を同定し、新規治療開発に向けて研究を進めています。

また肥大型心筋症患者の実態調査のためのレジストリー研究を実施しています(PREVAIL-HCM研究)。

発表論文

1. Novel Calmodulin Variant p.E46K Associated With Severe Catecholaminergic Polymorphic Ventricular Tachycardia Produces Robust Arrhythmogenicity in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Gao J, Makiyama T, Yamamoto Y, Kobayashi T, Aoki H, Maurissen TL, Wuriyanghai Y, Kashiwa A, Imamura T, Aizawa T, Huang H, Kohjitani H, Nishikawa M, Chonabayashi K, Fukuyama M, Manabe H, Nakau K, Wada T, Kato K, Toyoda F, Yoshida Y, Makita N, Woltjen K, Ohno S, Kurebayashi N, Murayama T, Sakurai T, Horie M, Kimura T.
   Circ Arrhythm Electrophysiol. 2023 Mar 3:e011387.

2. Disrupted CaV1.2 selectivity causes overlapping long QT and Brugada syndrome phenotypes in the CACNA1C-E1115K iPS cell model.
   Kashiwa A, Makiyama T, Kohjitani H, Maurissen TL, Ishikawa T, Yamamoto Y, Wuriyanghai Y, Gao J, Huang H, Imamura T, Aizawa T, Nishikawa M, Chonabayashi K, Mishima H, Ohno S, Toyoda F, Sato S, Yoshiura KI, Takahashi K, Yoshida Y, Woltjen K, Horie M, Makita N, Kimura T.
   Heart Rhythm. 2023 Jan;20(1):89-99.

3. Immunosuppressants Tacrolimus and Sirolimus revert the cardiac antifibrotic properties of p38-MAPK inhibition in 3D-multicellular human iPSC-heart organoids.
   Tian Y, Tsujisaka Y, Li VY, Tani K, Lucena-Cacace A*, Yoshida Y.*
   Front Cell Dev Biol. 2022 Nov 11;10:1001453.* Corresponding author

4. Hematopoietic stem progenitor cells with malignancy-related gene mutations in patients with acquired aplastic anemia are characterized by the increased expression of CXCR4.
   Katagiri T, Espinoza JL, Uemori M, Ikeda H, Hosokawa K, Ishiyama K, Yoroidaka T, Imi T, Takamatsu H, Ozawa T, Kishi H, Yamamoto Y, Elbadry MI, Yoshida Y, Chonabayashi K, Takenaka K, Akashi K, Nannya Y, Ogawa S, Nakao S.
   EJHaem. 2022 Jul 3;3(3):669-680.

5. Purification of human iPSC-derived cells at large scale using microRNA switch and magnetic-activated cell sorting.
   Tsujisaka Y, Hatani T, Okubo C, Ito R, Kimura A, Narita M, Chonabayashi K, Funakoshi S, Lucena-Cacace A, Toyoda T, Osafune K, Kimura T, Saito H*, Yoshida Y*.
   Stem Cell Reports. 2022 Jul 12;17(7):1772-1785.* Corresponding author

6. The GPI-anchored protein CD109 protects hematopoietic progenitor cells from undergoing erythroid differentiation induced by TGF-β.
   Tanabe M, Hosokawa K, Nguyen MAT, Nakagawa N, Maruyama K, Tsuji N, Urushihara R, Espinoza L, Elbadry MI, Mohiuddin M, Katagiri T, Ono M, Fujiwara H, Chonabayashi K, Yoshida Y, Yamazaki H, Hirao A, Nakao S.
   Leukemia. 2022 Mar;36(3):847-855.

7. Azacitidine is a potential therapeutic drug for pyridoxine-refractory female X-linked sideroblastic anemia.
   Morimoto Y, Chonabayashi K, Kawabata H, Okubo C, Yamasaki-Morita M, Nishikawa M, Narita M, Inagaki A, Nakanishi K, Nagao M, Takaori-Kondo A, Yoshida Y*.
   Blood Adv. 2022 Feb 22;6(4):1100-1114.* Corresponding author

8. CDH18 is a fetal epicardial biomarker regulating differentiation towards vascular smooth muscle cells.
   Junghof J, Kogure Y, Yu T, Verdugo-Sivianes EM, Narita M, Lucena-Cacace A*, Yoshida Y*.
   NPJ Regen Med. 2022 Feb 2;7(1):14.* Corresponding author

9. A versatile and robust cell purification system with an RNA-only circuit composed of microRNA-responsive ON and OFF switches.
   Fujita Y, Hirosawa M, Hayashi K, Hatani T, Yoshida Y, Yamamoto T, Saito H.
   Sci Adv. 2022 Jan 7;8(1):eabj1793.

10. Recent progress of iPSC technology in cardiac diseases.
    Funakoshi S, Yoshida Y*.
    Arch Toxicol. 2021 Dec;95(12):3633-3650. * Corresponding author

11. Expression dynamics of HAND1/2 in in vitro human cardiomyocyte differentiation.
    Okubo C, Narita M, Inagaki A, Nishikawa M, Hotta A, Yamanaka S, Yoshida Y*.
    Stem Cell Reports. 2021 Jul 8:S2213-6711(21)00322-2. * Corresponding author
12. ERRγ enhances cardiac maturation with T-tubule formation in human iPSC-derived cardiomyocytes.
    Miki K, Deguchi K, Nakanishi-Koakutsu M, Lucena-Cacace A, Kondo S, Fujiwara Y, Hatani T, Sasaki M, Naka Y, Okubo C, Narita M, Takei I, Napier S, Sugo T, Imaichi S, Monjo T, Ando T, Tamura N, Imahashi K, Nishimoto T, and Yoshida Y*.
    Nat Commun. 2021 Jun 21;12(1):3596. * Corresponding author
13. A frequent nonsense mutation in exon 1 across certain HLA-A and -B alleles in leukocytes of patients with acquired aplastic anemia.
    Mizumaki H, Hosomichi K, Hosokawa K, Yoroidaka T, Imi T, Zaimoku Y, Katagiri T, Anh Thi Nguyen M, Cao Tran D, Ibrahim Yousef Elbadry M, Chonabayashi K, Yoshida Y, Takamatsu H, Ozawa T, Azuma F, Kishi H, Fujii Y, Ogawa S, Tajima A, Nakao S.
    Haematologica. 2021 Jun 1;106(6):1581-1590.
14. Characterization of hiPSC-Derived Muscle Progenitors Reveals Distinctive Markers for Myogenic Cell Purification Toward Cell Therapy.
    Nalbandian M, Zhao M, Sasaki-Honda M, Jonouchi T, Lucena-Cacace A, Mizusawa T, Yasuda M, Yoshida Y, Hotta A, Sakurai H.
    Stem Cell Reports. 2021 Apr 13;16(4):883-898.
15. Making Cardiomyocytes from Pluripotent Stem Cells.
    Karagiannis P, Yoshida Y*.
    Methods Mol Biol. 2021;2320:3-7. doi: 10.1007/978-1-0716-1484-6_1. * Corresponding author
16. Isolation of Cardiomyocytes Derived from Human Pluripotent Stem Cells using miRNA switches.
    Miki K, Saito H*, Yoshida Y*.
    Methods Mol Biol. 2021;2320:35-51. * Corresponding author
17. Application of FluoVolt membrane potential dye for induced pluripotent stem cell-derived cardiac single cells and monolayers differentiated via embryoid bodies.
    Takaki T, Yoshida Y*.
    Methods Mol Biol. 2021;2320:101-110. * Corresponding author
18. Characterization of ventricular and atrial cardiomyocyte subtypes from human induced pluripotent stem cells.
    Kakutsu M, Takaki T, Miki K, Yoshida Y*.
    Methods Mol Biol. 2021;2320:135-149. * Corresponding author
19. A method for contraction force measurements of hiPSC-derived engineered cardiac tissues.
    Fujiwara Y, Deguchi K, Miki K, Nishimoto T, Yoshida Y*.
    Methods Mol Biol. 2021;2320:171-180. * Corresponding author
20. RNA-sequencing analysis of differentially expressed genes in human iPSC-derived cardiomyocytes.
    Okubo C*, Narita M, Yamamoto T*, Yoshida Y*.
    Methods Mol Biol. 2021;2320:193-217. * Corresponding author
21. Analysis of Transcriptional Profiling of Chamber-specific Human Cardiac Myocytes Derived from Pluripotent Stem Cells.
    Lucena-Cacace A*, Yoshida Y*.
    Methods Mol Biol. 2021;2320:219-232. * Corresponding author
22. Transplantation of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes in a Mouse Myocardial Infarction Model.
    Hatani T, Yoshida Y*.
    Methods Mol Biol. 2021;2320:285-293. * Corresponding author
23. Efficient Method to Dissociate Induced Pluripotent Stem Cell-Derived Cardiomyocyte Aggregates into Single Cells.
    Ito E, Miyagawa S, Yoshida Y, Sawa Y.
    Methods Mol Biol. 2021;2320:29-33.
24. Overview of the 84th Annual Scientific Meeting of the Japanese Circulation Society　- Change Practice!
    Ono K, Shizuta S, Yamamoto E, Saito N, Ozasa N, Kato T, Kato E, Horie T, Tazaki J, Shiomi H, Watanabe S, Watanabe H, Yamashita Y, Yoshikawa Y, Kinoshita H, Makiyama T, Yoshida Y, Ashida N, Nakagawa Y, Nakashima Y, Baba O, Kohjitani H, Kimura M, Inazumi H, Yoshizawa T, Komasa A, Kimura T.
    Circ J. 2021 Feb 25;85(3):323-329
25. Fukushima H, Yoshioka M, Kawatou M, López-Dávila V, Takeda M, Kanda Y, Sekino Y, Yoshida Y, Yamashita JK.
    Specific induction and long-term maintenance of high purity ventricular cardiomyocytes from human induced pluripotent stem cells.
    PLoS One. 2020 Nov 2;15(11):e0241287.
26. Okamoto R, Goto I, Nishimura Y, Kobayashi I, Hashizume R, Yoshida Y, Ito R, Kobayashi Y, Nishikawa M, Ali Y, Saito S, Tanaka T, Sawa Y, Ito M, Dohi K.
    Gap junction protein beta 4 plays an important role in cardiac function in humans, rodents, and zebrafish.
    PLoS One. 2020 Oct 13;15(10):e0240129.
27. Hirose S, Makiyama T, Melgari D, Yamamoto Y, Wuriyanghai Y, Yokoi F, Nishiuchi S, Harita T, Hayano M, Kohjitani H, Gao J, Kashiwa A, Nishikawa M, Wu J, Yoshimoto J, Chonabayashi K, Ohno S, Yoshida Y, Horie M, Kimura T.
    Propranolol Attenuates Late Sodium Current in a Long QT Syndrome Type 3-Human Induced Pluripotent Stem Cell Model.
    Front Cell Dev Biol. 2020 Aug 13;8:761.
28. Kuwabara Y, Tsuji S, Nishiga M, Izuhara M, Ito S, Nagao K, Horie T, Watanabe S, Koyama S, Kiryu H, Nakashima Y, Baba O, Nakao T, Nishino T, Sowa N, Miyasaka Y, Hatani T, Ide Y, Nakazeki F, Kimura M, Yoshida Y, Inada T, Kimura T, Ono K.
    Lionheart LincRNA alleviates cardiac systolic dysfunction under pressure overload.
    Commun Biol. 2020 Aug 13;3(1):434.
29. Nguyen MAT, Hosokawa K, Yoroidaka T, Maruyama H, Espinoza JL, Elbadry MI, Mohiuddin M, Tanabe M, Katagiri T, Nakagawa N, Chonabayashi K, Yoshida Y, Arima N, Kashiwase K, Saji H, Ogawa S, Nakao S.
    Resistance of KIR Ligand-Missing Leukocytes to NK Cells In Vivo in Patients with Acquired Aplastic Anemia.
    Immunohorizons. 2020 Jul 17;4(7):430-441.
30. Acute myeloid leukemia with a cryptic NUP98/PRRX2 rearrangement developing after low-dose methotrexate therapy for rheumatoid arthritis.
    Chonabayashi K, Yoshida Y, Kitawaki T, Nannya Y, Nakamura M, Oshima S, Hishizawa M, Yamashita K, Ogawa S, Takaori-Kondo A.
    Ann Hematol. 2019 Dec;98(12):2841-2843.
31. Elbadry MI, Mizumaki H, Hosokawa K, Espinoza JL, Nakagawa N, Chonabayashi K, Yoshida Y, Katagiri T, Hosomichi K, Zaimoku Y, Imi T, Nguyen MAT, Fujii Y, Tajima A, Ogawa S, Takenaka K, Akashi K, Nakao S.
    Escape hematopoiesis by HLA-B5401-lacking hematopoietic stem progenitor cells in men with acquired aplastic anemia.
    Haematologica. 2019 Oct;104(10):e447-e450.
32. Towards Precision Medicine With Human iPSCs for Cardiac Channelopathies.
    Wu JC, Garg P, Yoshida Y, Yamanaka S, Gepstein L, Hulot JS, Knollmann BC, Schwartz PJ.
    Circ Res. 2019 Aug 30;125(6):653-658.
33. Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility.
    Xu H, Wang B, Ono M, Kagita A, Fujii K, Sasakawa N, Ueda T, Gee P, Nishikawa M, Nomura M, Kitaoka F, Takahashi T, Okita K, Yoshida Y, Kaneko S, Hotta A.
    Cell Stem Cell. 2019 Apr 4;24(4):566-578.e7.
34. Takaki T, Inagaki A, Chonabayashi K, Inoue K, Miki K, Ohno S, Makiyama T, Horie M, Yoshida Y*.
    Optical recording of action potentials in human induced pluripotent stem cell-derived cardiac single cells and monolayers generated from long QT syndrome type 1 patient.
    Stem Cells Int. 2019 Mar 6;2019;7532657. * Corresponding author
35. Karagiannis P, Takahashi K, Saito M, Yoshida Y, Okita K, Watanabe A, Inoue H, Yamashita J, Todani M, Nakagawa M, Osawa M, Yashiro Y, Yamanaka S, Osafune K.
    Induced Pluripotent Stem Cells and Their Use in Human Models of Disease and Development.
    Physiol Rev. 2019 Jan 1;99(1):79-114.
36. Hatani T, Funakoshi S, Deerinck TJ, Bushong EA, Kimura T, Takeshima H, Ellisman MH, Hoshijima M, Yoshida Y*.
    Nano-structural analysis of engrafted human induced pluripotent stem cell-derived cardiomyocytes in mouse hearts using a genetic-probe APEX2.
    Biochem Biophys Res Commun. 2018 Nov 10;505(4):1251-1256. * Corresponding author
37. Wuriyanghai Y, Makiyama T*, Sasaki K, Kamakura T, Yamamoto Y, Hayano M, Harita T, Nishiuchi S, Chen J, Kohjitani H, Hirose S, Yokoi F, Gao J, Chonabayashi K, Watanabe K, Ohno S, Yoshida Y*, Kimura T, Horie M.
    Complex aberrant splicing in the induced pluripotent stem cell-derived cardiomyocytes from a patient with long-QT syndrome carrying KCNQ1-A344Aspl mutation.
    Heart rhythm 2018 Oct;15(10):1566-1574. * Corresponding author
38. Hatani T, Miki K, Yoshida Y*.
    Induction of Human Induced Pluripotent Stem Cells to Cardiomyocytes Using Embryoid Bodies.
    Methods Mol Biol. 2018;1816:79-92. * Corresponding author
39. Espinoza JL, Elbadry MI, Chonabayashi K, Yoshida Y, Katagiri T, Harada K, Nakagawa N, Zaimoku Y, Imi T, Hassanein HA, Khalifa A Noreldin A, Takenaka K, Akashi K, Hamana H, Kishi H, Akatsuka Y, Nakao S.
    Hematopoiesis by iPSC-derived hematopoietic stem cells of aplastic anemia that escape cytotoxic T-cell attack.
    Blood Adv. 2018 Feb 27;2(4):390-400.
40. Takeda M, Kanki Y, Masumoto H, Funakoshi S, Hatani T, Fukushima H, Izumi-Taguchi A, Matsui Y, Shimamura T, Yoshida Y, Yamashita JK.
    Identification of Cardiomyocyte-Fated Progenitors from Human-Induced Pluripotent Stem Cells Marked with CD82.
    Cell Rep. 2018 Jan 9;22(2):546-556.
41. Hayano M, Makiyama T*, Kamakura T, Watanabe H, Sasaki K, Funakoshi S, Wuriyanghai Y, Nishiuchi S, Harita T, Yamamoto Y, Kohjitani H, Hirose S, Yokoi F, Chen J, Baba O, Horie T, Chonabayashi K, Ohno S, Toyoda F, Yoshida Y*, Ono K, Horie M, Kimura T.
    The Development of a Patient-Derived Induced Pluripotent Stem Cell Model for the Investigation of SCN5A-D1275N-Related Cardiac Sodium Channelopathy.
    Circ J. 2017 Nov 24;81(12):1783-1791. * Corresponding author
42. Kawamura M, Miyagawa S, Fukushima S, Saito A, Miki K, Funakoshi S, Yoshida Y, Yamanaka S, Shimizu T, Okano T, Daimon T, Toda T, Sawa Y.
    Enhanced Therapeutic Effects of Human iPS Cell Derived-Cardiomyocyte by Combined Cell-Sheets with Omental Flap Technique in Porcine Ischemic Cardiomyopathy Model.
    Sci Rep. 2017 Aug 18;7(1):8824
43. Yoshida Y*, Yamanaka S.
    Induced Pluripotent Stem Cells Ten Years Later: For Cardiac Applications
    Circ Res. 2017 Jun 9;120(12):1958-1968. * Corresponding author
44. Kuang Y, Miki K, Parr CJ, Hayashi K, Takei I, Li J, Iwasaki M, Nakagawa M, Yoshida Y, Saito H.
    Efficient and Selective Removal of Human Pluripotent Stem Cells via Ecto-Alkaline Phosphatase-Mediated Aggregation of Synthetic Peptides
    Cell Chemical Biology. 2017 Jun 22;24(6):685-694.e4
45. Nakanishi H, Miki K, Komatsu KR, Umeda M, Mochizuki M, Inagaki A, Yoshida Y, Saito H.
    Monitoring and visualizing microRNA dynamics during live cell differentiation using microRNA-responsive non-viral reporter vectors
    Biomaterials. 2017 Jun;128:121-135.
46. Yamamoto Y, Makiyama T*, Harita T, Sasaki K, Wuriyanghai Y, Hayano M, Nishiuchi S, Kohjitani H, Hirose S, Chen J, Yokoi F, Ishikawa T, Ohno S, Chonabayashi K, Motomura H, Yoshida Y*, Horie M, Makita N*, Kimura T.
    Allele-specific ablation rescues electrophysiological abnormalities in a human iPS cell model of long-QT syndrome with a CALM2 mutation
    Hum Mol Genet. 2017 May 1;26(9):1670-1677. * Corresponding author
47. Ueki J, Nakamori M, Nakamura M, Nishikawa M, Yoshida Y, Tanaka A, Morizane A, Kamon M, Araki T, Takahashi MP, Watanabe A, Inagaki N, Sakurai M.
    Myotonic dystrophy type 1 patient-derived iPSCs for the investigation of CTG repeat instability
    Sci Rep. 2017 Feb 13;7:42522.
48. Sasaki K, Makiyama T*, Yoshida Y*, Wuriyanghai Y, Kamakura T, Nishiuchi S, Hayano M, Harita T, Yamamoto Y, Kohjitani H, Hirose S, Chen J, Itoh H, Kawamura M, Ohno S, Takeuchi A, Matsuoka S, Miura M, Sumitomo N, Horie M, Yamanaka S, Kimura T.
    Patient-specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia.
    Plos One. 2016 Oct 20;11(10):e0164795. * Corresponding author
49. Parr CJ, Katayama S, Miki K, Kuang Y, Yoshida Y, Morizane A, Takahashi J, Yamanaka S, Saito H.
    MicroRNA-302 switch to identify and eliminate undifferentiated human pluripotent stem cells.
    Sci Rep. 2016 Sep 9;6:32532.
50. Nishizawa M, Chonabayashi K, Nomura M, Tanaka A, Nakamura M, Inagaki A, Nishikawa M, Takei I, Oishi A, Tanabe K, Ohnuki M, Yokota H, Koyanagi-Aoi M, Okita K, Watanabe A, Takaori-Kondo A, Yamanaka S, Yoshida Y*
    Epigenetic variation between human induced pluripotent stem cell lines is an indicator of differentiation capacity.
    Cell Stem Cell. 2016 Sep 1;19(3):341-54. * Corresponding author
51. Oceguera-Yanez F, Kim SI, Matsumoto T, Tan GW, Xiang L, Hatani T, Kondo T, Ikeya M, Yoshida Y, Inoue H, Woltjen K.
    Engineering the AAVS1 locus for consistent and scalable transgene expression in human iPSCs and their differentiated derivatives.
    Methods. 2016 May 15;101:43-55.
52. Kawamura T, Miyagawa S, Fukushima S, Maeda A, Kashiyama N, Kawamura A, Miki K, Okita K, Yoshida Y, Shiina T, Ogasawara K, Miyagawa S, Toda K, Okuyama H, Sawa Y.
    Cardiomyocytes Derived from MHC-Homozygous Induced Pluripotent Stem Cells Exhibit Reduced Allogeneic Immunogenicity in MHC-Matched Non-human Primates.
    Stem Cell Reports. 2016 Mar 8;6(3):312-20
53. Morita Y, Andersen P, Hotta A, Tsukahara Y, Sasagawa N, Hayashida N, Koga C, Nishikawa M, Saga Y, Evans SM, Koshiba-Takeuchi K, Nishinakamura R, Yoshida Y, Kwon C, Takeuchi JK.
    Sall1 transiently marks undifferentiated heart precursors and regulates their fate.
    J Mol Cell Cardiol. 2016 Mar;92:158-62
54. Yoshida Y*, Yamanaka S.
    Understanding Intracellular Signaling Advances Cardiac Reprogramming Technology Toward Clinical Applications.
    Circ Res. 2016 Feb 5;118(3):377-8. * Corresponding author
55. Funakoshi S, Miki K, Takaki T, Okubo C, Hatani T, Chonabayashi K, Nishikawa M, Takei I, Oishi A, Narita M, Hoshijima M, Kimura T, Yamanaka S, Yoshida Y*
    Enhanced engraftment, proliferation, and therapeutic potential in heart using optimized human iPSC-derived cardiomyocytes.
    Sci Rep. 2016 Jan 8;6:19111. * Corresponding author
56. Miki K, Endo K, Takahashi S, Funakoshi S, Takei I, Katayama S, Toyoda T, Kotaka M, Takaki T, Umeda M, Okubo C, Nishikawa M, Oishi A, Narita M, Miyashita I, Asano K, Hayashi K, Osafune K, Yamanaka S, Saito H*, Yoshida Y*.
    Efficient Detection and Purification of Cell Populations Using Synthetic MicroRNA Switches
    Cell Stem Cell. 2015 Jun 4;16(6):699-711. * Corresponding author
57. Tokunaga K, Saitoh N, Goldberg I, Sakamoto C, Yasuda Y, Yoshida Y, Yamanaka S, Nakao M.
    Computational image analysis of colony and nuclear morphology　to evaluate human induced pluripotent stem cells
    Sci Rep. 2014 Nov 11;4:6996.
58. Nakagawa M, Taniguchi Y, Senda S, Takizawa N, Ichisaka T, Asano K, Morizane A, Doi D, Takahashi J, Nishizawa M, Yoshida Y, Toyoda T, Osafune K, Sekiguchi K, Yamanaka S.
    A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells.
    Sci Rep. 2014 Jan 8;4:3594.
59. Miki K, Yoshida Y*, Yamanaka S.
    Making Steady Progress on Direct Cardiac Reprogramming Toward Clinical Application
    Circ Res. 2013 Jun 21;113(1):13-5. * Corresponding author
60. Kamakura T, Makiyama T*, Sasaki K, Yoshida Y*, Wuriyanghai Y, Chen J, Hattori T, Ohno S, Kita T, Horie M, Yamanaka S, Kimura T.
    Ultrastructural Maturation of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes in a Long-Term Culture.
    Circ J. 2013 Apr 25;77(5):1307-14. * Corresponding author
61. Yoshida Y*, Yamanaka S.
    An emerging strategy of gene therapy for cardiac disease.
    Circ Res. 2012 Oct 12;111(9):1108-10. * Corresponding author
62. Yoshida Y*, Yamanaka S*
    Labor pains of new technology: direct cardiac reprogramming
    Circ Res. 2012 Jun 22;111(1):3-4 * Corresponding author
63. Yoshida Y*, Yamanaka S*
    iPS cells : A source of cardiac regeneration
    J Mol Cell Cardiol. 2011 Feb;50(2):327-32 * Corresponding author
64. Yoshida Y*, Yamanaka S*
    Induced pluripotent stem cells for disease modeling and stem cell-based regeneration
    Circulation. 2010 Jul 6;122(1):80-87 * Corresponding author
65. Yoshida, Y*, Takahashi, K, Okita, K, Ichisaka, T, and Yamanaka, S*.
    Hypoxia enhances the generation of induced pluripotent stem cells
    Cell Stem Cell. 2009 Sep 4;5(3):237-241. * Corresponding author
66. Nakashima Y, Ono K, Yoshida Y, Kojima Y, Kita T, Tanaka M, Kimura T.
    The search for Nkx2-5-regulated genes using purified embryonic stem cell-derived cardiomyocytes with Nkx2-5 gene targeting
    Biochem Biophys Res Commun. 2009 Dec 18;390(3):821-826
67. Kojima Y, Ono K, Inoue K, Takagi Y, Kikuta K, Nishimura M, Yoshida Y, Nakashima Y, Matsumae H, Furukawa Y, Mikuni N, Nobuyoshi M, Kimura T, Kita T, Tanaka M.
    Progranulin expression in advanced human atherosclerotic plaque.
    Atherosclerosis. 2009 Sep;206(1):102-8
68. Matsumae H, Yoshida Y, Ono K, Togi K, Inoue K, Furukawa Y, Nakashima Y, Kojima Y, Nobuyoshi M, Kita T, Tanaka M.
    CCN1 knockdown suppresses neointimal hyperplasia in a rat artery balloon injury model.
    Arterioscler Thromb Vasc Biol. 2008 Jun;28(6):1077-83.
69. Yoshida Y, Togi K, Matsumae H, Nakashima Y, Kojima Y, Yamamoto H, Ono K, Nakamura T, Kita T, Tanaka M.
    CCN1 protects cardiomyocytes from oxidative stress via beta1 integrin-Akt pathway.
    Biochem Biophys Res Commun. 2007 Apr 13; 355(3):611-8.
70. Kawamoto T, Togi K, Yamauchi R, Yoshida Y, Nakashima Y, Kita T, Tanaka M.
    Endothelin-1 activates Homer 1alpha expression via mitogen-activated protein kinase in cardiac　myocytes.
    Int J Mol Med. 2006 Jul;18(1):193-6.
71. Togi K, Yoshida Y, Matsumae H, Nakashima Y, Kita T, Tanaka M.
    Essential role of Hand2 in interventricular septum formation and trabeculation during cardiac development
    Biochem Biophys Res Commun. 2006 Apr 28; 343 (1):144-51.
72. Togi K, Kawamoto T, Yamauchi R, Yoshida Y, Kita T, Tanaka M.
    Role of Hand1/eHAND in the dorso-ventral patterning and interventricular septum formation in the embryonic heart.
    Mol Cell Biol. 2004 Jun; 24(11):4627-35.